Cargando…
Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and Osteosarcoma
Rexin-G, a pathotropic nanoparticle bearing a cytocidal cyclin G1 construct was tested in a phase I/II study for chemotherapy-resistant sarcomas and a phase II study for chemotherapy-resistant osteosarcoma. Twenty sarcoma patients and 22 osteosarcoma patients received escalating doses of Rexin-G int...
Autores principales: | Chawla, Sant P, Chua, Victoria S, Fernandez, Lita, Quon, Doris, Saralou, Andreh, Blackwelder, William C, Hall, Frederick L, Gordon, Erlinda M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835268/ https://www.ncbi.nlm.nih.gov/pubmed/19532136 http://dx.doi.org/10.1038/mt.2009.126 |
Ejemplares similares
-
Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer
por: Chawla, Sant P, et al.
Publicado: (2009) -
A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer
por: Chawla, Sant P., et al.
Publicado: (2018) -
Rexin-G(®), a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report
por: Kim, Seth, et al.
Publicado: (2017) -
SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma
por: Gordon, Erlinda Maria, et al.
Publicado: (2023) -
Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)
por: Chawla, Sant P., et al.
Publicado: (2023)